According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA (the Company’s lead product candidate, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to severe acute pain);
- as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays;
- the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.